A Open label, Vehicle Controlled Dermal Safety Study to Evaluate the Sensitizing Potential of Topically Applied 7 Different Colorant Formulations, Containing 4 Naturally Derived Colorants and its Formulations in Healthy Subjects Using a Single Patch Human Test Using Two Different Concentrations.

Plant Lipids P Limited0 个研究点目标入组 30 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 30

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•Males or females, age 21 to 65 years of age and in good general health
•Individuals of any skin type or race provided their degree of skin pigmentation does not significantly interfere with evaluations
•Individuals free of any systemic or dermatological disorder including known allergies to skin care products or topical drugs, or, other medical conditions which, in the opinion of the investigator, might interfere with the conduct of the study, interpretations of the results, or increase the risk of adverse reactions
•Individuals able to understand, and provide written informed consent.
•Individuals who are believed to be dependable, who agree to complete the course of the study, and comply with instructions.

排除标准

•Women who are self-reported pregnant, nursing or planning a pregnancy
•Individuals with a history of any dermatological disease or condition, including but not limited to active atopic dermatitis, psoriasis, eczema, active seasonal allergies or skin cancer within the past 6 months
•Individuals with abnormal skin pigmentation at the test sites which might interfere with subsequent evaluations of dermal responsiveness
•Individuals taking medications which might interfere with the test results, including any regimen of corticosteroids (equivalent to > 10 mg prednisone), steroidal/non-steroidal anti-inflammatory drugs, antihistamines or immunosuppressive drugs
•Individuals who have applied any type of topical anti-inflammatory medication to the test sites within two weeks prior to enrollment
•Individuals with any other skin condition that would interfere with the conduct of the study
•Individuals who have undergone a bilateral mastectomy with lymph node removal, a unilateral mastectomy with lymph node removal within the last year, or a bilateral axillary lymph node removal
•Individuals with a history of immune deficiency or auto-immune disease
•Individuals who are currently receiving allergy injections, have received allergy injections within one week prior to enrollment, or expect to begin receiving allergy injections during the study
•Individuals treated for malignancy within 6 months prior to enrollment
•Individuals who are currently under treatment for asthma or diabetes
•Current enrollment in any other research study or participation in a patch test study within 30 days prior to the start of this study
•Individuals who are known tape/adhesive reactors
•Treatment with ultraviolet (UV) light (including tanning) during the previous 3 weeks.
•Any psychiatric illness that prevents the subject from completing the study or interfere with the interpretation of the study results.

研究者

发起方

Plant Lipids P Limited

相似试验

进行中（未招募）

1 期

A study designed to explore reaction of the skin of healthy volunteers to Imiquimod cream.

EUCTR2016-000331-41-NLCentre for Human Drug Research16

已完成

不适用

A randomized, open-label, vehicle-controlled, parallel-cohort, dose-ranging study to explore the pharmacodynamics of topically applied imiquimod in healthy volunteers(dermatological challengemodel) (Skin inflammation model)1000381610014982

NL-OMON43402Centre for Human Drug Research16

进行中（未招募）

1 期

A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENTMedDRA version: 21.1Level: LLTClassification code 10043565Term: Thromboembolic eventSystem Organ Class: 100000004866Venous Thromboembolism

EUCTR2014-002606-20-PTBristol-Myers Squibb International Corporation150

进行中（未招募）

1 期

A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND EXTRAPOLATED EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENTMedDRA version: 20.0Level: LLTClassification code 10043565Term: Thromboembolic eventSystem Organ Class: 100000023033Venous Thromboembolism

EUCTR2014-002606-20-ESBristol-Myers Squibb International Corporation150

进行中（未招募）

1 期

A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND EXTRAPOLATED EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENTMedDRA version: 21.1Level: LLTClassification code 10043565Term: Thromboembolic eventSystem Organ Class: 100000004866Venous Thromboembolism

EUCTR2014-002606-20-GBBristol-Myers Squibb International Corporation250